FGNX vs SCYX Comparison

FG Nexus Inc operates through two primary segments: Digital Assets and Merchant Banking, with Digital Assets contributing the majority of revenue. The Company functions as a digital asset treasury, mainly holding Ethereum (ETH) and exploring opportunities in the tokenization of real-world assets, leveraging ETH as the foundation for digital finance, stablecoins, DeFi, and tokenized assets. The Merchant Banking segment offers strategic, administrative, and regulatory support to newly formed SPACs through the Company's SPAC platform.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.